PCSK9 inhibitors and cardiovascular outcomes in AMI-BIRISK patients: a multicenter retrospective study

Back

ESC2025 Premium Access

PCSK9 inhibitors and cardiovascular outcomes in AMI-BIRISK patients: a multicenter retrospective study

Session: Novel pharmacological approaches in acute coronary syndromes

Topic: Pharmacotherapy

Speaker: Doctor J. Ren (Tianjin, CN)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Jiayi Ren

2nd Hospital of Tianjin Medical University, Tianjin (China)

1 follower

5 more presentations in this session

Heart rate and cardiovascular outcomes with and without beta-blocker in post-mi patients: a pre-specified analysis of the ABYSS trial.

Speaker: Associate Professor M. Zeitouni (Paris, FR)

Access

Abstract

Slides

Inhibition of fractalkine signalling reduces intramyocardial haemorrhage and left ventricular thrombus in patients with acute myocardial infarction by modulating immunothrombosis (The FRACTAL trial)

Speaker: Professor I. Spyridopoulos (Newcastle-Upon-Tyne, GB)

Access

Abstract

Slides

Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis

Speaker: Mr V. Oliveira (Goiania, BR)

Access

Abstract

Slides

Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study

Speaker: Professor C. Su (Taichung, TW)

Access

Abstract

Slides

Long-term outcomes of prasugrel-based de-escalation versus conventional therapy after PCI in ACS patients

Speaker: Mr J. Yun (Seoul, KR)

Access

Abstract

Slides

Access the full session

Novel pharmacological approaches in acute coronary syndromes

Speakers: Doctor J. Ren, Associate Professor M. Zeitouni, Professor I. Spyridopoulos, Mr V. Oliveira, Professor C. Su...

Access

Video

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources